Teva Pharmaceutical Finance, guaranteed by Teva Pharmaceutical Industries Ltd. (TEVA, TEVA.TV) has revised pricing on its euro-denominated, benchmark-size, seven-year bond in the area of 105 basis points over midswaps, plus or minus five basis points, said one of the banks running the deal Thursday.

Initial price guidance was set between 115 to 120 basis points over midswaps.

BNP Paribas S.A., HSBC Holdings PLC, and JPMorgan Chase and Co., are the lead managers one the deal.

The deal has been rated A3 by Moody's Investors Service and A- by Standard & Poor's.

- By Sarka Halas, Dow Jones Newswires; +44 (0) 207 842 9236; Sarka.Halasova@dowjones.com